- This event has passed.
Endocannabinoid medicine; A gateway to psychedelic assisted psychotherapy [ONLINE]
January 13 @ 12:30 am - 2:00 am
by Mind Medicine Australia
With Dr Jamie Rickcord
Join this FREE, 60-minute online webinar to gain access to insights and learn about groundbreaking treatments to chronic mental health conditions.
The endocannabinoid system is essential for human homeostasis. An ancient signalling system ubiquitous in vertebrates. There is increasing evidence that ECS dysregulation results in numerous diseases as well inhibiting the bodies innate healing response. As we look to the future of psychedelic assisted therapy programmes endocannabinoid medicine will have a vital role to play in preparing people for the assisted psychotherapy process.
This session will explore:
What is the ECS?
How is the ECS involved in the development and treatment of PTSD / anxiety / depression?
How can we manipulate the ECS to improve assisted psychotherapy outcomes?
Following the presentation, there will be a Q & A panel with Dr Jamie Rickcord, Tania de Jong AM and Dr Alana Roy. This will be an opportunity to engage in a discussion about psychedelic-assisted psychotherapies for mental illness broadly, and what Mind Medicine Australia and other local organisations are doing here in Australia.
More about medicinal psychedelic treatments:
Psychedelic-assisted treatments offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.
The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive clinical outcomes in large trials that are currently underway.